<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36982160</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>07</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Systemic Lupus Erythematosus and Pulmonary Hypertension.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5085</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24065085</ELocationID><Abstract><AbstractText>Pulmonary Hypertension (PH) is a common manifestation in patients with Systemic Lupus Erythematosus (SLE) and varies from asymptomatic to life-threatening disease. PH can result not only from immune system dysregulation, but also from various conditions, including cardiorespiratory disorders and thromboembolic diseases. Most commonly, SLE-related PH presents with non-specific symptoms, such as progressive dyspnea on exertion, generalized fatigue and weakness and eventually dyspnea at rest. Prompt diagnosis of SLE-related PH and early identification of the underlying pathogenetic mechanisms is demanded in order to introduce targeted therapy to prevent irreversible pulmonary vascular damage. In most cases the management of PH in SLE patients is similar to idiopathic pulmonary arterial hypertension (PAH). Furthermore, specific diagnostic tools like biomarkers or screening protocols, to establish early diagnosis seem to be not available yet. Although, the survival rates for patients with SLE-related PH vary between studies, it is evident that PH presence negatively affects the survival of SLE patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parperis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medical School, University of Cyprus, Nicosia CY2024, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velidakis</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1909-0048</Identifier><AffiliationInfo><Affiliation>Medical School, University of Cyprus, Nicosia CY2024, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khattab</LastName><ForeName>Elina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical School, University of Cyprus, Nicosia CY2024, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkougkoudi</LastName><ForeName>Evangelia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Medical School, University of Cyprus, Nicosia CY2024, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadoglou</LastName><ForeName>Nikolaos P E</ForeName><Initials>NPE</Initials><Identifier Source="ORCID">0000-0002-7830-3488</Identifier><AffiliationInfo><Affiliation>Medical School, University of Cyprus, Nicosia CY2024, Cyprus.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065627" MajorTopicYN="N">Familial Primary Pulmonary Hypertension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="Y">Thromboembolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">medical treatment</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">pulmonary arterial hypertension (PAH)</Keyword><Keyword MajorTopicYN="N">pulmonary hypertension (PH)</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus (SLE)</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36982160</ArticleId><ArticleId IdType="pmc">PMC10049584</ArticleId><ArticleId IdType="doi">10.3390/ijms24065085</ArticleId><ArticleId IdType="pii">ijms24065085</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barber M.R.W., Drenkard C., Falasinnu T., Hoi A., Mak A., Kow N.Y., Svenungsson E., Peterson J., Clarke A.E., Ramsey-Goldman R. Global epidemiology of systemic lupus erythematosus. Nat. Rev. Rheumatol. 2021;17:515&#x2013;532. doi: 10.1038/s41584-021-00668-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00668-1</ArticleId><ArticleId IdType="pmc">PMC8982275</ArticleId><ArticleId IdType="pubmed">34345022</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly P.M., Parton H., Wang L., McCune W.J., Lim S.S., Drenkard C., Ferucci E.D., Dall&#x2019;Era M., Gordon C., Helmick C.G., et al. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021;73:991&#x2013;996. doi: 10.1002/art.41632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41632</ArticleId><ArticleId IdType="pmc">PMC8169527</ArticleId><ArticleId IdType="pubmed">33474834</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojan G., Petri M. Epidemiology of systemic lupus erythematosus: An update. Curr. Opin. Rheumatol. 2018;30:144&#x2013;150. doi: 10.1097/BOR.0000000000000480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000480</ArticleId><ArticleId IdType="pmc">PMC6026543</ArticleId><ArticleId IdType="pubmed">29251660</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A., Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J. Autoimmun. 2019;96:1&#x2013;13. doi: 10.1016/j.jaut.2018.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannah J.R., D&#x2019;Cruz D.P. Pulmonary Complications of Systemic Lupus Erythematosus. Semin. Respir. Crit. Care Med. 2019;40:227&#x2013;234. doi: 10.1055/s-0039-1685537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1685537</ArticleId><ArticleId IdType="pubmed">31137062</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera-Pickens G., Abud-Mendoza C. Pulmonary manifestations in systemic lupus erythematosus: Pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage. Reumatol. Clin. 2018;14:294&#x2013;300. doi: 10.1016/j.reuma.2018.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2018.03.012</ArticleId><ArticleId IdType="pubmed">29773465</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonneau G., Montani D., Celermajer D.S., Denton C.P., Gatzoulis M.A., Krowka M., Williams P.G., Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 2019;53:1801913. doi: 10.1183/13993003.01913-2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01913-2018</ArticleId><ArticleId IdType="pmc">PMC6351336</ArticleId><ArticleId IdType="pubmed">30545968</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarnani R., Yeoh S.A., Denneny E.K., Wincup C. Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus. Front. Med. 2021;7:610257. doi: 10.3389/fmed.2020.610257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.610257</ArticleId><ArticleId IdType="pmc">PMC7847931</ArticleId><ArticleId IdType="pubmed">33537331</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K., Urowitz M.B. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr. Rheumatol. Rev. 2017;13:206&#x2013;218. doi: 10.2174/1573397113666170704102444.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573397113666170704102444</ArticleId><ArticleId IdType="pubmed">28675998</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: Current status and future direction. Clin. Dev. Immunol. 2012;2012:854941. doi: 10.1155/2012/854941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/854941</ArticleId><ArticleId IdType="pmc">PMC3318206</ArticleId><ArticleId IdType="pubmed">22489252</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabu A., Patel K., Yee C.S., Nightingale P., Situnayake R.D., Thickett D.R., Townend J.N., Gordon C. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology. 2009;48:1506&#x2013;1511. doi: 10.1093/rheumatology/kep203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep203</ArticleId><ArticleId IdType="pubmed">19671698</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittoo S., Fell C.D. Pulmonary manifestations of systemic lupus erythematosus. Semin. Respir. Crit. Care Med. 2014;35:249&#x2013;254. doi: 10.1055/s-0034-1371537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1371537</ArticleId><ArticleId IdType="pubmed">24668539</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y., Zhang X., Feng Y., Wang J., Luo R. Risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus. Cardiol. Young. 2021;31:1619&#x2013;1624. doi: 10.1017/S1047951121000688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1047951121000688</ArticleId><ArticleId IdType="pubmed">33682659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian F., Chen D., Wang Y., Ye Y., Wang X., Zhan Z., Xu H., Liang L., Yang X. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol. Int. 2012;32:1727&#x2013;1731. doi: 10.1007/s00296-011-1880-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-011-1880-4</ArticleId><ArticleId IdType="pubmed">21437686</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Que W., Zheng X., Zou S., Li P., Yang X. Clinical Features and Risk Factors of Pulmonary Hypertension in Chinese Patients With Systemic Lupus Erythematosus. Arch. Rheumatol. 2018;34:88&#x2013;95. doi: 10.5606/ArchRheumatol.2019.6780.</Citation><ArticleIdList><ArticleId IdType="doi">10.5606/ArchRheumatol.2019.6780</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y.F., Robbins I.M., Karatas M., Brixey A.G., Rice T.W., Light R.W. Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases. Chest. 2011;140:42&#x2013;47. doi: 10.1378/chest.10-0227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.10-0227</ArticleId><ArticleId IdType="pubmed">21212140</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Wang Q., Zhao J., Li Z., Ye Z., Li C., Li X., Zhu P., Wang Z., Zheng Y., et al. Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus. 2014;23:1085&#x2013;1091. doi: 10.1177/0961203314527366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314527366</ArticleId><ArticleId IdType="pubmed">24651670</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Li M., Liu Y., Wang Q., Guo X., Zhao J., Lai J., Tian Z., Zhao Y., Zeng X. Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. Medicine. 2016;95:e2761. doi: 10.1097/MD.0000000000002761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000002761</ArticleId><ArticleId IdType="pmc">PMC4998855</ArticleId><ArticleId IdType="pubmed">26962774</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K., Gladman D.D., Urowitz M.B. Systemic lupus erythematosus and pulmonary arterial hypertension: Links, risks, and management strategies. Open Access Rheumatol. 2016;9:1&#x2013;9. doi: 10.2147/OARRR.S123549.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OARRR.S123549</ArticleId><ArticleId IdType="pmc">PMC5191623</ArticleId><ArticleId IdType="pubmed">28053559</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao M., Zhang C., Gao C., Wang Q., Dai M., Yue R., Sun W., Liang W., Zheng Z. Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Systemic Lupus Erythematosus and Pulmonary Arterial Hypertension: Evidence From Transcriptome Data. Front. Immunol. 2021;12:658341. doi: 10.3389/fimmu.2021.658341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.658341</ArticleId><ArticleId IdType="pmc">PMC8320323</ArticleId><ArticleId IdType="pubmed">34335565</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M., Sugimoto A., Atsumi T. Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: Current recommendations and recent advances. Expert Rev. Clin. Immunol. 2020;16:993&#x2013;1004. doi: 10.1080/1744666X.2021.1825940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1825940</ArticleId><ArticleId IdType="pubmed">32975145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kommireddy S., Bhyravavajhala S., Kurimeti K., Chennareddy S., Kanchinadham S., Rajendra Vara Prasad I., Rajasekhar L. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: An observational study. Rheumatology. 2015;54:1673&#x2013;1679. doi: 10.1093/rheumatology/kev097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev097</ArticleId><ArticleId IdType="pubmed">25929760</ArticleId></ArticleIdList></Reference><Reference><Citation>Jais X., Launay D., Yaici A., Le Pavec J., Tch&#xe9;rakian C., Sitbon O., Simonneau G., Humbert M. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58:521&#x2013;531. doi: 10.1002/art.23303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23303</ArticleId><ArticleId IdType="pubmed">18240255</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Li H., Shi J., He B., Yu F. Complement alternative pathway activation associated with pulmonary hypertension in lupus nephritis patients. Lupus. 2019;28:1051&#x2013;1061. doi: 10.1177/0961203319860192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319860192</ArticleId><ArticleId IdType="pubmed">31296141</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson S.R., Granton J.T. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur. Respir. Rev. 2011;20:277&#x2013;286. doi: 10.1183/09059180.00003811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09059180.00003811</ArticleId><ArticleId IdType="pmc">PMC9487746</ArticleId><ArticleId IdType="pubmed">22130821</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonigk D., Golpon H., Bockmeyer C.L., Maegel L., Hoeper M.M., Gottlieb J., Nickel N., Hussein K., Maus U., Lehmann U., et al. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am. J. Pathol. 2011;179:167&#x2013;179. doi: 10.1016/j.ajpath.2011.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.03.040</ArticleId><ArticleId IdType="pmc">PMC3123793</ArticleId><ArticleId IdType="pubmed">21703400</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans C.E., Cober N.D., Dai Z., Stewart D.J., Zhao Y.Y. Endothelial cells in the pathogenesis of pulmonary arterial hypertension. Eur. Respir. J. 2021;58:2003957. doi: 10.1183/13993003.03957-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03957-2020</ArticleId><ArticleId IdType="pmc">PMC8316496</ArticleId><ArticleId IdType="pubmed">33509961</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Lopez L., Cardona-Mu&#xf1;oz E.G., Celis A., Garc&#xed;a-de la Torre I., Orozco-Barocio G., Salazar-Paramo M., Garcia-Gonzalez C., Garcia-Gonzalez A., Sanchez-Ortiz A., Trujillo-Hernandez B., et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus. 2004;13:105&#x2013;112. doi: 10.1191/0961203304lu509oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203304lu509oa</ArticleId><ArticleId IdType="pubmed">14995003</ArticleId></ArticleIdList></Reference><Reference><Citation>Quismorio F.P.J., Sharma O., Koss M., Boylen T., Edmiston A.W., Thornton P.J., Tatter D. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin. Arthritis Rheum. 1984;13:349&#x2013;359. doi: 10.1016/0049-0172(84)90015-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-0172(84)90015-5</ArticleId><ArticleId IdType="pubmed">6374900</ArticleId></ArticleIdList></Reference><Reference><Citation>George P.M., Oliver E., Dorfmuller P., Dubois O.D., Reed D.M., Kirkby N.S., Mohamed N.A., Perros F., Antigny F., Fadel E., et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ. Res. 2014;114:677&#x2013;688. doi: 10.1161/CIRCRESAHA.114.302221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.114.302221</ArticleId><ArticleId IdType="pmc">PMC4006084</ArticleId><ArticleId IdType="pubmed">24334027</ArticleId></ArticleIdList></Reference><Reference><Citation>Asif S., Rasheed A., Mahmud T.E., Asghar A. Frequency and predictors of pulmonary hypertension in patients with Systemic Lupus Erythematosus. Pak. J. Med. Sci. 2019;35:86&#x2013;89. doi: 10.12669/pjms.35.1.405.</Citation><ArticleIdList><ArticleId IdType="doi">10.12669/pjms.35.1.405</ArticleId><ArticleId IdType="pmc">PMC6408637</ArticleId><ArticleId IdType="pubmed">30881402</ArticleId></ArticleIdList></Reference><Reference><Citation>Pope J. An update in pulmonary hypertension in systemic lupus erythematosus&#x2014;Do we need to know about it? Lupus. 2008;17:274&#x2013;277. doi: 10.1177/0961203307087188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307087188</ArticleId><ArticleId IdType="pubmed">18413406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A., Tziolos N., Bertsias G., Boumpas D.T. Update &#x3bf;n the diagnosis and management of systemic lupus erythematosus. Ann. Rheum. Dis. 2021;80:14&#x2013;25. doi: 10.1136/annrheumdis-2020-218272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K.C. Pulmonary fibrosis, part I: Epidemiology, pathogenesis, and diagnosis. Expert Rev. Respir. Med. 2017;11:343&#x2013;359. doi: 10.1080/17476348.2017.1312346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17476348.2017.1312346</ArticleId><ArticleId IdType="pubmed">28345383</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang I.M., Campean I.A., Sadushi-Kolici R., Badr-Eslam R., Gerges C., Skoro-Sajer N. Chronic Thromboembolic Disease and Chronic Thromboembolic Pulmonary Hypertension. Clin. Chest. Med. 2021;42:81&#x2013;90. doi: 10.1016/j.ccm.2020.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2020.11.014</ArticleId><ArticleId IdType="pubmed">33541619</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M., Kovacs G., Hoeper M.M., Badagliacca R., Berger R.M.F., Brida M., Carlsen J., Coats A.J.S., Escribano-Subias P., Ferrari P., et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2023;61:2200879. doi: 10.1183/13993003.00879-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00879-2022</ArticleId><ArticleId IdType="pubmed">36028254</ArticleId></ArticleIdList></Reference><Reference><Citation>Galderisi M., Cosyns B., Edvardsen T., Cardim N., Delgado V., Di Salvo G., Donal E., Sade L.E., Ernande L., Garbi M., et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: An expert consensus document of the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging. 2017;18:1301&#x2013;1310. doi: 10.1093/ehjci/jex244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jex244</ArticleId><ArticleId IdType="pubmed">29045589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.J., Baek I.W., Park Y.J., Yoon C.H., Kim W.U., Cho C.S. High levels of uric acid in systemic lupus erythematosus is associated with pulmonary hypertension. Int. J. Rheum. Dis. 2015;18:524&#x2013;532. doi: 10.1111/1756-185X.12262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12262</ArticleId><ArticleId IdType="pubmed">24428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Mart&#xed;nez D., Marroqu&#xed;n-Fabi&#xe1;n E., Lozada-Navarro A.C., Mora-Ram&#xed;rez M., Ju&#xe1;rez M., S&#xe1;nchez-Mu&#xf1;oz F., Vargas-Barr&#xf3;n J., Sandoval J., Amezcua-Guerra L.M. Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: A seven-year follow-up study. Lupus. 2016;25:61&#x2013;66. doi: 10.1177/0961203315600539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315600539</ArticleId><ArticleId IdType="pubmed">26306740</ArticleId></ArticleIdList></Reference><Reference><Citation>Min H.K., Lee J.H., Jung S.M., Lee J., Kang K.Y., Kwok S.K., Ju J.H., Park K.S., Park S.H. Pulmonary hypertension in systemic lupus erythematosus: An independent predictor of patient survival. Korean J. Intern. Med. 2015;30:232&#x2013;241. doi: 10.3904/kjim.2015.30.2.232.</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2015.30.2.232</ArticleId><ArticleId IdType="pmc">PMC4351331</ArticleId><ArticleId IdType="pubmed">25750566</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Li M., Chen Y., Wang Q., Tian Z., Pan S., Zeng X., Ye S. Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol. 2015;67:2394&#x2013;2402. doi: 10.1002/art.39212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39212</ArticleId><ArticleId IdType="pubmed">26018988</ArticleId></ArticleIdList></Reference><Reference><Citation>Cefle A., Inanc M., Sayarlioglu M., Kamali S., Gul A., Ocal L., Aral O., Konice M. Pulmonary hypertension in systemic lupus erythematosus: Relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol. Int. 2011;31:183&#x2013;189. doi: 10.1007/s00296-009-1255-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-009-1255-2</ArticleId><ArticleId IdType="pubmed">20012052</ArticleId></ArticleIdList></Reference><Reference><Citation>Asherson R.A., Harris E.N., Bernstein R.M., Mackworth-Young C.G., Hughes G.R. Immunological studies in &#x2018;primary&#x2019; idiopathic pulmonary hypertension. Eur. J. Rheumatol. Inflamm. 1984;7:75&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">6336293</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuily S., Domingues V., Suty-Selton C., Eschw&#xe8;ge V., Bertoletti L., Chaouat A., Chabot F., Regnault V., Horn E.M., Erkan D., et al. Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis. Autoimmun. Rev. 2017;16:576&#x2013;586. doi: 10.1016/j.autrev.2017.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.04.003</ArticleId><ArticleId IdType="pubmed">28411166</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu J., Li M., Wang Y., Duan X., Luo H., Zhao C., Zhan F., Wu Z., Li H., Yang M., et al. Predicting the Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: A Chinese Systemic Lupus Erythematosus Treatment and Research Group Cohort Study. Arthritis Rheumatol. 2021;73:1847&#x2013;1855. doi: 10.1002/art.41740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41740</ArticleId><ArticleId IdType="pubmed">34105259</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel S.R., Omar G.M., Darwish A.F., Asklany H.T., Ellabban A.S. Asymptomatic pulmonary hypertension in systemic lupus erythematosus. Clin. Med. Insights Arthritis Musculoskelet. Disord. 2011;4:77&#x2013;86. doi: 10.4137/CMAMD.S7667.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/CMAMD.S7667</ArticleId><ArticleId IdType="pmc">PMC3201107</ArticleId><ArticleId IdType="pubmed">22084605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow S.L., Chandran V., Fazelzad R., Johnson S.R. Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension. Lupus. 2012;21:353&#x2013;364. doi: 10.1177/0961203311429815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311429815</ArticleId><ArticleId IdType="pubmed">22127457</ArticleId></ArticleIdList></Reference><Reference><Citation>Gussin H.A., Ignat G.P., Varga J., Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:376&#x2013;383. doi: 10.1002/1529-0131(200102)44:2&lt;376::AID-ANR56&gt;3.0.CO;2-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200102)44:2&lt;376::AID-ANR56&gt;3.0.CO;2-2</ArticleId><ArticleId IdType="pubmed">11229469</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C., Li M., Liu J., Qian J., Xu D., Zhang S., Li P., Zhao J., Tian X., Zeng X. Anti-SmD1 antibodies are associated with renal disorder, seizures, and pulmonary arterial hypertension in Chinese patients with active SLE. Sci. Rep. 2017;7:7617. doi: 10.1038/s41598-017-08099-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-08099-3</ArticleId><ArticleId IdType="pmc">PMC5548929</ArticleId><ArticleId IdType="pubmed">28790444</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizus M., Li J., Goldman D., Petri M.A. Autoantibody clustering of lupus-associated pulmonary hypertension. Lupus Sci. Med. 2019;6:e000356. doi: 10.1136/lupus-2019-000356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000356</ArticleId><ArticleId IdType="pmc">PMC6928462</ArticleId><ArticleId IdType="pubmed">31908817</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghdashi M., Behnemoon M., Mahmoodi Rad J., Rabiepour M. Evaluation of serum uric acid level in systemic lupus erythematosus patients with normal and high pulmonary arterial hypertension. Biomedicine. 2018;8:23&#x2013;28. doi: 10.1051/bmdcn/2018080316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/bmdcn/2018080316</ArticleId><ArticleId IdType="pmc">PMC6108231</ArticleId><ArticleId IdType="pubmed">30141403</ArticleId></ArticleIdList></Reference><Reference><Citation>Depascale R., Del Frate G., Gasparotto M., Manfr&#xe8; V., Gatto M., Iaccarino L., Quartuccio L., De Vita S., Doria A. Diagnosis and management of lung involvement in systemic lupus erythematosus and Sj&#xf6;gren&#x2019;s syndrome: A literature review. Ther. Adv. Musculoskelet. Dis. 2021;13:1759720X211040696. doi: 10.1177/1759720X211040696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X211040696</ArticleId><ArticleId IdType="pmc">PMC8488521</ArticleId><ArticleId IdType="pubmed">34616495</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M.S., Usman M.S., Siddiqi T.J., Khan S.U., Murad M.H., Mookadam F., Figueredo V.M., Krasuski R.A., Benza R.L., Rich J.D. Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension? Circ. Cardiovasc. Qual. Outcomes. 2018;11:e004757. doi: 10.1161/CIRCOUTCOMES.118.004757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.118.004757</ArticleId><ArticleId IdType="pmc">PMC7453961</ArticleId><ArticleId IdType="pubmed">30354550</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D., Savale L., Natali D., Ja&#xef;s X., Herve P., Garcia G., Humbert M., Simonneau G., Sitbon O. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur. Heart J. 2010;31:1898&#x2013;1907. doi: 10.1093/eurheartj/ehq170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehq170</ArticleId><ArticleId IdType="pubmed">20543192</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez O., Sitbon O., Ja&#xef;s X., Simonneau G., Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130:182&#x2013;189. doi: 10.1378/chest.130.1.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.130.1.182</ArticleId><ArticleId IdType="pubmed">16840400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwana M., Blair C., Takahashi T., Langley J., Coghlan J.G. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: Post hoc analysis. Ann. Rheum. Dis. 2020;79:626&#x2013;634. doi: 10.1136/annrheumdis-2019-216274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-216274</ArticleId><ArticleId IdType="pmc">PMC7213337</ArticleId><ArticleId IdType="pubmed">32161055</ArticleId></ArticleIdList></Reference><Reference><Citation>Badesch D.B., Hill N.S., Burgess G., Rubin L.J., Barst R.J., Gali&#xe8; N., Simonneau G., SUPER Study Group Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J. Rheumatol. 2007;34:2417&#x2013;2422.</Citation><ArticleIdList><ArticleId IdType="pubmed">17985403</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M., Coghlan J.G., Ghofrani H.A., Grimminger F., He J.G., Riemekasten G., Vizza C.D., Boeckenhoff A., Meier C., de Oliveira Pena J., et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: Results from PATENT-1 and PATENT-2. Ann. Rheum. Dis. 2017;76:422&#x2013;426. doi: 10.1136/annrheumdis-2015-209087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-209087</ArticleId><ArticleId IdType="pmc">PMC5284330</ArticleId><ArticleId IdType="pubmed">27457511</ArticleId></ArticleIdList></Reference><Reference><Citation>Oudiz R.J., Schilz R.J., Barst R.J., Gali&#xe9; N., Rich S., Rubin L.J., Simonneau G., Treprostinil Study Group Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126:420&#x2013;427. doi: 10.1378/chest.126.2.420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.126.2.420</ArticleId><ArticleId IdType="pubmed">15302727</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins I.M., Gaine S.P., Schilz R., Tapson V.F., Rubin L.J., Loyd J.E. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000;117:14&#x2013;18. doi: 10.1378/chest.117.1.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.117.1.14</ArticleId><ArticleId IdType="pubmed">10631192</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaine S., Chin K., Coghlan G., Channick R., Di Scala L., Gali&#xe8; N., Ghofrani H.A., Lang I.M., McLaughlin V., Preiss R., et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur. Respir. J. 2017;50:1602493. doi: 10.1183/13993003.02493-2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02493-2016</ArticleId><ArticleId IdType="pmc">PMC5593379</ArticleId><ArticleId IdType="pubmed">28818881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachulla E., Jais X., Cinquetti G., Clerson P., Rottat L., Launay D., Cottin V., Habib G., Prevot G., Chabanne C., et al. Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry. Chest. 2018;153:143&#x2013;151. doi: 10.1016/j.chest.2017.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2017.08.014</ArticleId><ArticleId IdType="pubmed">28851621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobanski V., Giovannelli J., Lynch B.M., Schreiber B.E., Nihtyanova S.I., Harvey J., Handler C.E., Denton C.P., Coghlan J.G. Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol. 2016;68:484&#x2013;493. doi: 10.1002/art.39432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39432</ArticleId><ArticleId IdType="pubmed">26415038</ArticleId></ArticleIdList></Reference><Reference><Citation>Condliffe R., Kiely D.G., Peacock A.J., Corris P.A., Gibbs J.S., Vrapi F., Das C., Elliot C.A., Johnson M., DeSoyza J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am. J. Respir. Crit. Care Med. 2009;179:151&#x2013;157. doi: 10.1164/rccm.200806-953OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200806-953OC</ArticleId><ArticleId IdType="pubmed">18931333</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y.J., Jiang X., Zhou W., Wang Y., Gao L., Wang Y., Li G.T., Hong T., Huo Y., Jing Z.C., et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur. Respir. J. 2014;44:963&#x2013;972. doi: 10.1183/09031936.00182813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00182813</ArticleId><ArticleId IdType="pubmed">24791829</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>